AIGH Capital Management LLC Grows Position in PolyPid Ltd. $PYPD

AIGH Capital Management LLC boosted its position in shares of PolyPid Ltd. (NASDAQ:PYPD) by 18.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,593,587 shares of the company’s stock after purchasing an additional 250,615 shares during the period. PolyPid comprises 1.0% of AIGH Capital Management LLC’s holdings, making the stock its 24th biggest holding. AIGH Capital Management LLC owned approximately 0.08% of PolyPid worth $6,980,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC bought a new stake in PolyPid in the fourth quarter worth about $451,000. XTX Topco Ltd grew its stake in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after buying an additional 10,888 shares during the last quarter. Jane Street Group LLC bought a new position in shares of PolyPid during the fourth quarter valued at approximately $66,000. HighTower Advisors LLC purchased a new stake in shares of PolyPid in the fourth quarter worth approximately $44,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after buying an additional 3,500 shares during the period. 26.47% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on PYPD. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings upgraded PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.67.

PolyPid Price Performance

Shares of PYPD opened at $5.21 on Thursday. The firm has a market capitalization of $99.41 million, a price-to-earnings ratio of -2.73 and a beta of 1.40. PolyPid Ltd. has a 1-year low of $3.06 and a 1-year high of $5.61. The company has a 50-day moving average of $4.74 and a 200 day moving average of $4.52.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, May 13th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.12. On average, equities analysts anticipate that PolyPid Ltd. will post -1.34 earnings per share for the current fiscal year.

PolyPid Company Profile

PolyPid Ltd is a clinical?stage biotechnology company focused on polymer?based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus?Penetrating (MMP) platform, PolyPid develops long?acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer?formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.